BOSTON, MA – Kiran Mazumdar-Shaw, founder of biopharmaceutical company Biocon, has named her niece Claire Mazumdar as her successor, outlining a formal succession plan for the company, according to a ...
Bladder cancer continues to be one of the most frequently diagnosed malignancies worldwide, with current treatments such as surgery and chemotherapy often ...
A Spectra Physics Model A supermarket scanner—one of the first ten ever produced. A laser within the unit projects a beam onto a mirror that redirects it through the glass plate on the top. Cade ...
Biocon is already the world’s third-largest insulin supplier by volume Rising diabetes rates in emerging markets are expected to lift demand Mazumdar-Shaw called the market gap a windfall for Biocon’s ...
AI Quick Read Mumbai: Indian drugmaker Biocon Ltd. is aiming to become the world’s top supplier of insulin in the coming years, co-founder Kiran Mazumdar-Shaw said, by capturing growing demand for the ...
Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial Patients with nonmetastatic ...
Hosted on MSN
USD 5.5 billion deal: Biocon to merge biologics unit; to acquire stake held by Serum, Mylan
USD 5.5 billion deal: Biocon, an innovation-driven global biopharmaceuticals company, on Saturday, December 6 2025, announced a strategic move to fully integrate Biocon Biologics Limited (BBL) as a ...
AI can be used by consumers for basic health questions to save time spent with real-life doctors, according to Alex Zhavoronkov, CEO of Insilico Medicine. OpenAI and Amazon launched health care tools ...
Biocon Biologics established its first North American headquarters right here in the great Garden State, selecting Bridgewater as the site. The global biosimilars company announced the location this ...
These new assets are among the largest oncology biologics scheduled to lose exclusivity over the next five years and will join Biocon Biologics’ existing portfolio of 17 oncology medications, which ...
Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary. The Viatris stake is one of ...
I write about Asia's richest, fast-growing businesses, and startups. Biocon—controlled by Indian pharmaceutical billionaire Kiran Mazumdar-Shaw—is buying the rest of privately held subsidiary Biocon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results